BSMV Viral-Like Particles Microbial Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for producing Barley stripe mosaic virus (BSMV) nanoparticles are limited by in-planta production, which is costly, time-consuming, and subject to evolutionary pressures that can destabilize engineered modifications, and requires specialized facilities due to the virus's nature as a plant pathogen.
Innovation Solution
A microbial expression system is used to produce BSMV viral-like particles (VLPs) by introducing a nucleic acid sequence encoding a BSMV coat protein with an origin of self-assembly (OAS) and site-directed mutations, allowing for self-assembly and customization of nanoparticle dimensions through linker regions, enabling high-yield and stable nanoparticle synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If in-planta production methods are used for BSMV, then viral nanoparticles can be produced, but the process becomes costly, time-consuming, and requires specialized facilities
Solution Approach 1:
The patent creates viral-like particles (VLPs) that copy the structure and self-assembly properties of authentic BSMV viruses without containing viral genetic material. These VLPs are produced using microbial expression systems (bacteria, yeast, insects, or mammals) instead of plant hosts, eliminating the need for specialized plant facilities while maintaining nanoparticle production capabilities. The VLPs replicate the functional morphology and nanometric precision of viral nanoparticles without the harmful biological constraints of living virus production.
Solution Approach 2:
The patent replaces the biological self-replication mechanism of viruses in plants with a biochemical self-assembly system. The VLPs are assembled through controlled self-assembly of coat protein subunits in microbial cells, using biochemical processes rather than viral replication machinery. This substitution eliminates the need for plant host systems, specialized facilities, and complex viral life cycle management, while achieving high-yield nanoparticle production through standardized biochemical processes.
2Reliability
If in-planta production is used for BSMV, then nanoparticles can be synthesized, but evolutionary pressures may remove engineered modifications
Solution Approach 1:
The patent produces VLPs that copy the structural and functional properties of BSMV without containing replicating viral genomes. Since the VLPs lack viral genetic material, they cannot undergo evolutionary selection pressures that would remove engineered modifications. The coat protein sequences can be statically designed with specific mutations (such as D101N, E62Q, or other stabilizing mutations) that remain fixed and stable, preserving engineered characteristics for nanoparticle synthesis applications.
Solution Approach 2:
The patent employs site-directed mutations in the coat protein sequence to stabilize the VLP structure and prevent disassembly under various conditions. Specific amino acid changes (such as mutating Asp101 to Asn, Glu62 to Gln, or other conservative substitutions) are introduced to enhance structural stability without affecting self-assembly capability. These parameter changes in the protein sequence allow the VLPs to maintain engineered modifications stable while retaining nanoparticle formation functionality.
3Quantity of substance
If conventional BSMV production methods are used, then nanoparticles can be produced, but the viral replication cycle requires 2-3 weeks and yields relatively small quantities
Solution Approach 1:
The patent replaces the slow viral replication cycle in plants with rapid microbial protein expression systems. The VLPs are produced by introducing plasmids encoding the coat protein into microbial cells (such as E. coli), which can replicate and assemble nanoparticles within hours rather than weeks. This substitution of the production system accelerates the timeline from 2-3 weeks to approximately 16-20 hours while increasing the quantity of nanoparticles produced through high-yield microbial fermentation processes.
Solution Approach 2:
The patent optimizes expression parameters including temperature (e.g., 18-25°C to stabilize VLP structure), induction conditions, and protein folding modifiers to enhance VLP assembly efficiency. By controlling these parameters, the system achieves high yields of properly folded, self-assembled VLPs in a fraction of the time required for viral replication, scaling production from milligrams to grams per liter of culture medium.
4Stability of the object's composition
If BSMV VLPs are produced with strengthened subunit interactions, then nanoparticle stability is enhanced, but the complexity of protein engineering increases
Solution Approach 1:
The patent introduces specific point mutations in the coat protein sequence that strengthen subunit interactions and stabilize VLP structure. Common mutations include Asp101→Asn, Glu62→Gln, or other conservative substitutions at key interface residues. These parameter changes in the protein sequence are targeted and specific, enhancing stability without requiring complete redesign of the protein structure. The mutations are introduced using standard site-directed mutagenesis techniques, maintaining engineering complexity at manageable levels while achieving significant stability improvements.
Solution Approach 2:
The patent applies localized mutations at specific positions in the coat protein sequence where subunit interactions occur. Rather than modifying the entire protein structure, the approach focuses on specific local regions (such as residue 101, 62, or other interface positions) where strengthening subunit contacts is most effective. This localized quality approach enhances nanoparticle stability through minimal, targeted changes, avoiding the complexity of global protein redesign while achieving the desired structural reinforcement.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for efficient, scalable, and genetically customizable production of BSMV nanoparticles with enhanced stability and metal coating capabilities, overcoming the limitations of in-planta methods and providing a cost-effective solution for nanoparticle synthesis.
Implementation Method 1
The BSMV-CP subunits self-assemble into viral-like particles through non-covalent interactions
Implementation Method 2
The BSMV-CP subunits self-assemble into viral-like particles through non-covalent interactions
Implementation Method 3
Metal ions can coordinate with amino acid residues on the virus capsid surface through electrostatic attraction
Data Source
AI summary
Methods and nucleic acid sequences for the synthesis of biotemplates in a non-plant based expression system are provided. Such biotemplates include Barley stripe mosaic virus viral-like particles (BSMV-VLPs) that are capable of self-assembly due to being operatively linked with an origin of self-assembly with the Barley stripe mosaic virus capsid protein (BSMV-CP). Also provided are BSMV-VLPs that are capable of self-assembly due one or more site-directed mutations on the BSMV-CP, and BSMV-VLPs that exhibit enhanced stability due to such site-directed mutation(s).